Skip to main content

Table 2 Summary of key points from the literature review

From: The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach

Question Key literature review results
How has the COVID-19 pandemic impacted the individual with SCZ or BP-I? Individuals recently diagnosed with SCZ or BP-I are at increased risk of COVID-19 infection, compared with individuals without a mental disorder [25].
A SCZ spectrum diagnosis is associated with mortality after COVID-19 diagnosis [26].
Mental health problems are likely to remain increased beyond the actual pandemic [27].
What is the impact of the COVID-19 pandemic on treatment challenges for individuals with SCZ and BP-I? The start of the COVID-19 pandemic resulted in reduced access to services, early psychiatric discharge, and disruption to face-to-face psychiatric care for people with pre-existing mental illness, potentially increasing relapse and suicide risk [9].
What are the main gaps to the access of healthcare during and after the COVID-19 pandemic and the utility of LAIs? LAI prescriptions decreased at the start of the COVID-19 pandemic, driven by a decrease in face-to-face consultations as part of pandemic-related physical distancing measures. Individuals require the most consistent (and convenient) access to LAIs [20, 21].
  1. BP-I bipolar I disorder, LAI long-acting injectable antipsychotics, SCZ schizophrenia